George Kelly, MD
Rheumatology · Las Vegas, NVNPI 1619944113
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $137,801 of the $184,896 with a category attached, or 74.5%. 27 manufacturers reported payments, led by AbbVie at 54.9% of the total. Reporting peaked in 2019 at $67,150 and has fallen 78.6% since, to $14,350 in 2025. Among rheumatology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,179 payments — averaging $156.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$102K
- Amgen$23K
- GSK$22K
- Novartis$19K
- Lilly USA, LLC$9K
- UCB, Inc.$3K
- plus $7K from 21 others
Across 90 payments — averaging $10,377 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$315K
- UCB SA$293K
- AbbVie$163K
- Pfizer$47K
- Amgen$41K
- Eli Lilly$29K
- plus $46K from 4 others
What the payments were for
- Consulting fees$6,9754%
- Speaking & faculty fees$137,80175%
- Grants$2400%
- Travel & lodging$16,2569%
- Food & beverage$23,39913%
- Education$2250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 274 | $101,561 |
| Amgen(2 entities) | 157 | $22,784 |
| GSK | 74 | $22,412 |
| Novartis | 127 | $19,500 |
| Lilly USA, LLC | 70 | $8,667 |
| UCB, Inc. | 116 | $3,314 |
| Johnson & Johnson | 117 | $1,669 |
| E.r. Squibb & Sons, L.L.C. | 63 | $733 |
| Pfizer | 29 | $641 |
| Genentech USA, Inc. | 30 | $462 |
| Aurinia Pharma U.S., Inc. | 7 | $429 |
| Organon | 17 | $366 |
| ANI Pharmaceuticals, Inc. | 15 | $365 |
| Radius Health, Inc. | 17 | $356 |
| Sanofi | 8 | $355 |
| AstraZeneca(2 entities) | 14 | $249 |
| Boehringer Ingelheim | 6 | $215 |
| Mallinckrodt Hospital Products Inc. | 9 | $182 |
| Sobi, Inc | 9 | $174 |
| Sandoz | 7 | $163 |
| Kyowa Kirin, Inc. | 4 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Tersera Therapeutics LLC | 1 | $46 |
| Bristol Myers Squibb | 2 | $43 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Medexus Pharma, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,896 in reported general payments places this provider in the 95th percentile of 43 rheumatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 118 | $944,082 |
| Enbrel SureclickEtanercept | 79 | $703,807 |
| RinvoqUpadacitinib | 46 | $327,500 |
| EnbrelEtanercept | 40 | $311,452 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $266,164 |
| OrenciaAbatacept | 32 | $192,853 |
| Humira(Cf)Adalimumab | 21 | $192,834 |
| SimponiGolimumab | 14 | $160,459 |
| Xeljanz XrTofacitinib Citrate | 19 | $118,269 |
| TymlosAbaloparatide | 41 | $112,321 |
| BenlystaBelimumab | 13 | $64,682 |
| KevzaraSarilumab | 12 | $53,681 |
| RemicadeInfliximab | 12 | $49,412 |
| ProliaDenosumab | 25 | $43,767 |
| Hydroxychloroquine Sulfate | 618 | $27,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $101,561 | $520,33467 claims |
| AmgenEnbrel, Prolia | $22,784 | $355,21965 claims |
| Johnson & JohnsonSimponi, Remicade | $1,669 | $209,87026 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $733 | $192,85332 claims |
| Radius Health, Inc.Tymlos | $356 | $112,32141 claims |
| GSKBenlysta | $22,412 | $64,68213 claims |
| SanofiKevzara | $355 | $53,68112 claims |
| Boehringer IngelheimCombivent Respimat | $215 | $8,71014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 rheumatology providers in Nevada.
Other rheumatology in Las Vegas
- Ewa OlechLas Vegas$287K
- Walter ChathamLas Vegas$197K
- Nasim DaoudLas Vegas$109K
- William KimLas Vegas$16K
- Aida LoudyiLas Vegas$10K
- Tudor JianuLas Vegas$8K
- Khalil Ibrahim BourjiLas Vegas$7K
- Neil BraunsteinLas Vegas$6K
- Michael CliffordLas Vegas$4K
- Chen TangLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.